KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Johnson & Johnson (JNJ) EBITDA (2016 - 2026)

Johnson & Johnson's EBITDA history spans 18 years, with the latest figure at $6.4 billion for Q1 2026.

  • On a quarterly basis, EBITDA rose 2.93% to $6.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $40.1 billion, a 88.39% increase, with the full-year FY2025 number at $39.9 billion, up 89.98% from a year prior.
  • EBITDA hit $6.4 billion in Q1 2026 for Johnson & Johnson, down from $20.1 billion in the prior quarter.
  • Over the last five years, EBITDA for JNJ hit a ceiling of $20.1 billion in Q4 2025 and a floor of $3.6 billion in Q4 2024.
  • Historically, EBITDA has averaged $7.4 billion across 5 years, with a median of $5.9 billion in 2024.
  • Biggest five-year swings in EBITDA: plummeted 80.91% in 2024 and later surged 457.46% in 2025.
  • Tracing JNJ's EBITDA over 5 years: stood at $5.3 billion in 2022, then surged by 255.78% to $18.9 billion in 2023, then plummeted by 80.91% to $3.6 billion in 2024, then surged by 457.46% to $20.1 billion in 2025, then plummeted by 68.28% to $6.4 billion in 2026.
  • Business Quant data shows EBITDA for JNJ at $6.4 billion in Q1 2026, $20.1 billion in Q4 2025, and $7.0 billion in Q3 2025.